The changing face of hypophosphatemic disorders in the FGF-23 era.
The changing face of hypophosphatemic disorders in the FGF-23 era.
复制标题
DOI：
--
复制
发表时间：
2013-06
期刊：
影响因子：
--
通讯作者：
Janet Y. Lee;E. Imel
中科院分区：
文献类型：
--
作者：
Janet Y. Lee;E. Imel
在过去的十年中，对低磷血症遗传性疾病的研究极大地扩展了我们对磷酸盐代谢的理解。 X连锁低磷血症（XLH）是由于肾脏磷酸盐消耗导致的佝偻病最常见的遗传形式。最近对疾病机制以及成纤维细胞生长因子 23 (FGF-23) 在 XLH 和其他低磷血症疾病中的作用的了解开辟了新的潜在治疗途径。我们将讨论 XLH 的当前治疗标准以及正在研究的有前途的未来方向。
In the past decade, research in genetic disorders of hypophosphatemia has significantly expanded our understanding of phosphate metabolism. X-linked hypophosphatemia (XLH) is the most common inherited form of rickets due to renal phosphate wasting. Recent understanding of the mechanisms of disease and role of fibroblast growth factor 23 (FGF-23) in XLH and other hypophosphatemic disorders have opened new potential therapeutic avenues. We will discuss the current standard of treatment for XLH as well as promising future directions under study.